Objectives: Although treatment disparities in diabetes have been documented along racial/ethnic lines, it is unclear if immigrant groups in the United States experience similar treatment disparities. Our objective was to determine whether immigrant status is associated with differences in pharmacological treatment of diabetes in a nationally representative sample of adults with diabetes. We were specifically interested in differences in treatment with oral hypoglycemic agents (OHA) and insulin. Pharmacological treatment of diabetes differs along immigrant status lines. To understand these findings, studies capturing the processes underlying treatment differences in diabetes among immigrants are needed. Findings raise the possibility that integrating information about a patient's immigrant status, in addition to racial/ethnic identity, may be an important component of culturally sensitive diabetes care.
treatment disparities (Golden et al., 2012) . Indeed, treatment decision making for diabetes, including the initiation and intensification of treatment, is complicated by a host of economic, social, and cultural considerations (Davidson, 2005) that operate within and between the patient, provider, and health care system and that contribute to racial/ethnic disparities (J. B. Brown et al., 2002) . What is less understood, however, is whether immigrant groups face health disparities similar to racial/ethnic minorities. This knowledge is important because (a) immigrants are projected to compose about 18% of the U.S. population by 2065 (Pew Research Center, 2015) and (b) immigrants are at an elevated risk of diabetes and shoulder a substantial proportion of the diabetes burden (OzaFrank, Chan, Liu, Burke, & Kanaya, 2010; Oza-Frank & Narayan, 2010) . Because immigrants are clustered within certain racial/ ethnic groups, examining treatment disparities along racial/ethnic lines can reveal some information about how to enhance the health of and care for the growing immigrant population. However, it fails to capture unique factors that make immigrant groups particularly vulnerable to health care disparities overall and for diabetes in particular (Derose, Escarce, & Lurie, 2007; Lebrun, 2012; Siddiqi, Zuberi, & Nguyen, 2009) .
The immigrant population in the United States is a heterogeneous group that varies in terms of race and ethnicity, English proficiency, premigration conditions, and U.S. settlement experiences, among other factors (A. Brown & Stepler, 2016) . Nonetheless, many immigrants encounter similar conditions that can create vulnerabilities to health inequity (Derose et al., 2007) . To illustrate, immigrants tend to have lower rates of health insurance, to use health care less often, and to receive lower quality of care than those born in United States (Derose et al., 2007) . In addition, recent trends in local and national immigration policies have not only made it more difficult for immigrants to access care but have also stigmatized certain immigrant groups, including undocumented immigrants and refugees (Hacker, Anies, Folb, & Zallman, 2015; Hacker et al., 2011; Martinez et al., 2015) . As such, we examine immigrant status as a potentially important social determinant of health in general and of diabetes health in particular.
The objective of the present study was to determine whether immigrant status is associated with differences in pharmacological treatment of diabetes. The ADA recommends a patient-centered approach to diabetes treatment, which includes considering comorbidities and patient preferences. For people with newly diagnosed Type 2 diabetes, the ADA recommends initiating metformin, an oral hypoglycemic agent (OHA). For newly diagnosed people who are symptomatic or who have more severe glycemic measures, the ADA recommends initiating insulin therapy. In addition, for those who have not met or maintained glycemic goals after three months on noninsulin monotherapy, the ADA recommends (a) adding a second agent, (b) adding a glucagon-like peptide 1 receptor agonist, or (c) adding insulin. It is important to note that the ADA notes that, for people not achieving glycemic goals, insulin therapy should not be delayed (ADA, 2016a) . Here, we examined immigrant status differences in OHA and insulin treatment. Although OHAs are usually the first-line treatment, many patients will need their treatment intensified to achieve or maintain glycemic control (ADA, 2016a) . Failure to initiate insulin, or failure to intensify from OHAs to insulin, can result in an unnecessarily prolonged period of poor glycemic control and, thus, can play a major role in serious diabetes complications (ADA, 2016b; Nathan, 2002; Simons-Morton, Genuth, Byington, Gerstein, & Friedewald, 2005) . Because U.S. immigrant groups tend to receive lowerquality health care (Derose, Bahney, Lurie, & Escarce, 2009; Derose et al., 2007) , we hypothesized that, among people with diabetes, those who were foreign-born would be less likely to receive intensified diabetes treatment (i.e., insulin) compared with their U.S.-born peers.
Method Study Design and Sample
The institutional review board at Indiana University-Purdue University Indianapolis approved this archival study. We examined data from the 2003-2012 survey years of the continuous National Health and Nutrition Examination Survey (NHANES). The NHANES program of studies is intended to assess the health and nutritional status of adults and children in the U.S. NHANES employs a cross-sectional, stratified, multistage probability design to capture a nationally representative sample of the civilian, noninstitutionalized U.S. population. Detailed descriptions of the survey design and procedures are available on the NHANES website (www.cdc.gov/nchs/nhanes.htm). Briefly, about 5,000 individuals were recruited each 2-year survey cycle. In NHANES, respondents were first asked to complete a computer-assisted in-home interview conducted by trained personnel to assess demographic, nutrition, and health-related factors. Respondents elected to complete the interview in English, in Spanish, or through an interpreter. Approximately 1-2 weeks after the in-home interview, all respondents were asked to attend a Mobile Examination Center (MEC) to undergo physical examinations, laboratory assessments, and additional interviews.
From the total sample for the 2003-2012 survey years (N ϭ 50,912), we first selected all respondents aged 18 years or older (n ϭ 29,802). We then selected all respondents who reported a diabetes diagnosis (n ϭ 3,252, 10.9%). Diabetes diagnosis was determined by the question asked during the in-home interview, "Have you ever been told by a doctor or other health professional that you have diabetes or sugar diabetes?" Only respondents answering "Yes" were included in our sample. Thus, respondents were excluded if they answered "No," "Borderline or Prediabetes," "Refused," "Don't Know," or did not answer this question. From the cohort of 3,252 respondents with self-reported diabetes, we excluded respondents with missing data for country of birth (n ϭ 1) or demographic factors (n ϭ 340). We also excluded respondents with missing data for kidney disease (n ϭ 7), retinopathy (n ϭ 15), hemoglobin (Hb) A1c levels (n ϭ 123), duration of the diabetes diagnosis (n ϭ 23), clinical CVD (n ϭ 27), hypertension (n ϭ 8), hypercholesterolemia (n ϭ 233), smoking status (n ϭ 0), and height/weight measurements (n ϭ 179). Because diabetes severity, duration of diabetes diagnosis, and CVD, and its risk factors can all influence diabetes treatment decisions (Berry, Tardif, & Bourassa, 2007; Uwaifo & Ratner, 2007) , it is important to include these factors as covariates in models predicting diabetes treatment received. Finally, we excluded respondents with missing diabetes medication data (n ϭ 36). The characteristics of our final sample of 2,260 respondents with self-reported diabetes are shown in Table 1 . This document is copyrighted by the American Psychological Association or one of its allied publishers.
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Measures
Immigrant status. Country of birth was assessed during the in-home interview. Between 2003 Between -2006 , respondents could identify themselves as being "Born in the 50 U.S. States or Washington, D.C.," "Born in Mexico," "Born Elsewhere," "Refused," or "Don't Know." Between 2007-2010, "Born Elsewhere" was removed and replaced with "Born in Other Spanish Speaking Country" and "Born in Other Non-Spanish Speaking Country." Beginning in 2011-2012, the response options changed to "Born in 50 U.S. States or Washington, D.C.," "Others," "Refused," and "Don't Know." To maintain consistency across these survey years, we computed a dichotomous immigrant status variable coded as U.S.-born (0 ϭ respondent reported being born in one of the 50 U.S. States or Washington, DC) or foreign-born (1 ϭ respondent reported being born outside of the 50 U.S. States or Washington, DC, including U.S. territories).
Diabetes medication. During the in-home interview, respondents were asked if they had taken any prescription medications in the past month. Those who reported taking one or more prescription medications were asked to provide the medication containers to the interviewer, who then recorded the medication name. If the respondent was unable to produce containers, s/he was asked to provide the medication names. Each medication was recorded in an online database, where it was matched with its drug type, generic name, and therapeutic class code. Using these data, we identified all reported OHAs and insulins in our final sample. We coded respondents as yes (1) on the OHA treatment variable if they reported taking any of the following medications in the past Note. Continuous variables presented as mean and SD, categorical variables presented as n and %. GED ϭ general education diploma; AA ϭ associate degree. This document is copyrighted by the American Psychological Association or one of its allied publishers.
month: metformin, glipizide, pioglitazone, glyburide, glimepiride, sitagliptin, rosiglitazone, colesevelam, nateglinide, repaglinide, acarbose, saxagliptin, miglitol, linagliptin, chlorpropamide, gliclazide, or tolazamide. Otherwise, we coded them as no (0). Similarly, we coded respondents as yes (1) on the insulin treatment variable if they reported taking any of the following forms of insulin in the past month: insulin aspart, insulin aspart protamine, insulin glargine, insulin lispro, insulin lispro protamine, insulin isophane, insulin regular, insulin determir, insulin glulisine, insulin zinc, or insulin zinc extended. Otherwise, we coded them as no (0). From these variables, we created a 3-level variable to capture respondents taking neither OHA nor insulin (none), those taking one or more OHAs without insulin (OHA only), and those taking insulin with or without an OHA (insulin only/insulin ϩ OHA).
Covariates. Models included the following demographic covariates: age (years), sex (0 ϭ male, 1 ϭ female), four dummy variables for race/ethnicity (reference group: non-Hispanic White), four dummy variables for education level (reference group: college graduate or above), poverty income ratio (PIR), and marital status (0 ϭ married/living with partner, 1 ϭ single/widowed/divorced/ separated). Between survey years 2003-2010, NHANES included five race/ethnicity categories: non-Hispanic White, non-Hispanic Black, Mexican American, other Hispanic, and other race including multiracial. A sixth category (non-Hispanic Asian) was added in 2011-2012, which we combined with the "other race" category to maintain consistency across survey years. During the in-home interview, respondents reported their highest level of education, from which we created five categories: less than 9th grade, 9th-11th grade with no diploma, high school diploma or GED, some college or associate degree, and college graduate or above. Respondents were also asked to report total annual family income or total annual individual income for the last calendar year. From these data, a continuous PIR (possible range: 0.0 -5.0) was calculated by dividing family or individual annual income by the federal poverty level threshold published in the Census Bureau's Current Population Reports for a specific survey year. A PIR value below 1.0 indicates that the family/individual lives below the poverty threshold. Because PIR values were capped at 5.0, families/individuals with PIR values above this level were recorded as 5.0.
Subsequent models further accounted for (a) diabetes severity and duration indicators, and (b) clinical CVD and its risk factors. Diabetes severity and duration indicators were a history of kidney disease (0 ϭ no, 1 ϭ yes), presence of retinopathy (0 ϭ no, 1 ϭ yes), HbA1c (%; a measure of blood glucose control over last 120 days; Saudek, Derr, & Kalyani, 2006) , and duration of diabetes diagnosis (years; current age minus age of diabetes diagnosis). Kidney disease, retinopathy, and age of diabetes diagnosis were assessed during the in-home interview, and HbA1c was measured at the MEC. Respondents were coded as having clinical CVD (0 ϭ no, 1 ϭ yes) if they reported a history of coronary artery disease, angina, myocardial infarction, stroke, or congestive heart failure during the in-home interview. CVD risk factors were history of hypertension (0 ϭ no, 1 ϭ yes), history of hypercholesterolemia (0 ϭ no, 1 ϭ yes), two dummy variables for smoking status (never vs. current smoker and never vs. former smoker), and body mass index (BMI; kg/m 2 ). Hypertension, hypercholesterolemia, and smoking status were assessed during the in-home interview, and height and weight for the computation of BMI were measured at the MEC.
Supplemental models additionally adjusted for the potential confounders of health care factors and language. Health care factors were health insurance status, routine health care access, and past-year health care visits. During the in-home interview, respondents were asked if they were covered by health insurance or another health care plan (0 ϭ no, 1 ϭ yes). They were also asked if they had a place where they usually go when sick or needing advice about health (0 ϭ no/do not know, 1 ϭ yes/there is more than one place). In addition, respondents were asked how many times they had seen a doctor or other health care professional in the past 12 months, not including overnight stays, from which we computed two dummy-coded variables (none to three times vs. four to nine times and none to three times vs. 10 or more times). Finally, language of the in-home interview (0 ϭ English without an interpreter, 1 ϭ Spanish or English through an interpreter) served as an indicator for respondent preference for/comfort with speaking English.
Data Analysis
All analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, NC). We first performed t tests and chisquare (
2 ) tests to examine differences between foreign-born and U.S.-born respondents on study variables. To account for survey design factors including oversampling, nonresponse, and poststratification, we applied appropriate NHANES sampling design weighted variables to all models described below. Applying sample weights allows each respondent to represent the proportion of the population s/he represents, thus providing estimates representative of the U.S. civilian noninstitutionalized population (see www.cdc.gov/nchs/tutorials/nhanes/SurveyDesign/Weighting/intro .htm for details). We used sample weights from the MEC subsample because certain covariates (e.g., HbA1c) were available for this subsample only.
To determine whether immigrant status is associated with differences in diabetes treatment with medications, we ran two multinomial logistic regression models. We first examined the association between immigrant status and our 3-level diabetes treatment variable (none, OHA only, insulin only/insulin ϩ OHA) using none as the reference group. The first model included demographic factors (age, sex, four dummy variables for race/ethnicity, four dummy variables for education level, PIR, and marital status) as covariates. The second model further adjusted for diabetes severity and duration indicators (kidney disease, retinopathy, HbA1c, and duration of diabetes diagnosis), clinical CVD, and CVD risk factors (hypertension, hypercholesterolemia, two dummy variables for smoking status, and BMI).
Supplemental models additionally adjusted for health insurance status, past-year health care visits, and language. To maintain a reasonable predictor-to-event ratio, each of these variables was entered individually and removed before entering the next variable. This resulted in three supplemental models. We also computed a routine access to health care variable; however, the number of respondents reporting not having routine access was very low. Thus, we did not include this variable in a supplemental model. None of the respondents in our final sample were missing data for health care factors or language. This document is copyrighted by the American Psychological Association or one of its allied publishers.
Results

Respondent Characteristics
Approximately one quarter (23.4%) of our final sample was foreign-born. As shown in Table 1 , we observed several significant differences between the foreign-born and U.S.-born groups on the respondent characteristics. First, foreign-born respondents were younger, less likely to be non-Hispanic White or non-Hispanic Black, and more likely to be Mexican American, other Hispanic, or other race/multiracial. Foreign-born respondents were more likely to have less than a 9th grade education, less likely to have completed up to a high school/GED level of education, and less likely to have completed up to some college or associate degree. Foreignborn respondents had lower poverty income ratios (i.e., live closer to the poverty line) and were more likely to be married or living with a partner. Second, foreign-born respondents were less likely to have a history of kidney disease, had higher HbA1c levels, and had shorter duration of diabetes diagnosis. Third, foreign-born respondents were less likely to have clinical CVD or a history of hypertension. Foreign-born respondents were more likely to have never been a smoker, less likely to be a current smoker, and less likely to be a former smoker and had lower BMI values. Finally, foreign-born respondents were less likely to have health insurance, more likely to have used health care between 0 and 3 times in the past year, less likely to have used health care more than 10 times in the last year, and more likely to have completed the survey in a language other than English. 
Association of Immigrant Status With OHA-Only Treatment
As shown in Figure 1 , multinomial logistic regression models using no treatment as the reference group revealed that the association between immigrant status and the odds of OHA-only treatment fell just short of significance in both the demographicadjusted model (p ϭ .060) and the fully adjusted model (p ϭ .065), despite having potentially meaningful effect sizes (ORs ϭ 1.58 and 1.59, respectively). In the supplemental models that additionally adjusted for health insurance, past-year health care visits, and language one at a time, being foreign-born was generally associated with increased odds of OHA-only treatment (odds ratio [OR] We observed associations, generally in the expected directions, between the covariates and OHA-only treatment that are of potential interest (see Table 2 ). In the fully adjusted model, less than 9th grade education (p ϭ .017), 9th-11th grade education (p ϭ .022), and higher poverty income ratio (p ϭ .025) were independently associated with an increased odds of OHA only treatment. In the supplemental models, having health insurance (p ϭ .002) was also independently associated with an increased odds of OHA-only treatment.
Association of Immigrant Status With Insulin Treatment
As can be seen in Figure 1 , multinomial logistic regression models using no treatment as the reference group indicated that immigrant status was significantly associated with the odds of insulin treatment (insulin only/insulin ϩ OHA). Compared with being U.S.-born, being foreign-born was associated with a 53% decreased odds of being treated with insulin in the demographicadjusted model (p ϭ .011) and a 47% decreased odds in the fully adjusted model (p ϭ .047). In supplemental models, adjusting for Figure 1 . Forest plot summarizing odds ratio estimates of association of being foreign-born with OHA-only treatment and insulin (insulin only/insulin ϩ OHA) Treatment. The reference group is none (no OHA or insulin treatment). The demographics-adjusted model is adjusted for age, sex, race/ethnicity, education, poverty income ratio, marital status, and the NHANES sampling design. The fully adjusted model is further adjusted for kidney disease, retinopathy, hemoglobin A1c level, duration of diabetes diagnosis, clinical cardiovascular disease, hypertension, hypercholesterolemia, smoking status, and body mass index. OHA ϭ oral hypoglycemic agent; OR ϭ odds ratio; CI ϭ confidence interval; NHANES ϭ National Health and Nutrition Examination Survey. This document is copyrighted by the American Psychological Association or one of its allied publishers.
health insurance, past-year health care visits, and language one at a time attenuated the immigrant status-insulin treatment relationship, but the magnitude of the association remained large (OR ϭ 0. We again detected associations between the covariates and insulin treatment (see Table 2 ). A history of retinopathy (p Ͻ .001), higher HbA1c (p Ͻ .001), longer duration of diabetes diagnosis (p Ͻ .001), clinical CVD (p ϭ .014), and higher BMI (p ϭ .046) were independently associated with an increased odds of insulin treatment, whereas older age (p ϭ .003) and a history of hypertension (p ϭ .017) were independently associated with a decreased odds. In the supplemental models, having health insurance (p Ͻ .001) and having 10 ϩ past-year health care visits (p ϭ .021) were also associated with an increased odds of insulin treatment.
Discussion
Our objective was to determine whether immigrant status is associated with differences in pharmacological treatment of diabetes. In a large, nationally representative sample of adults with diabetes, we found that foreign-born people were only half as likely to be treated with insulin as U.S.-born people. Critically, this group difference persisted after adjustment for numerous potential confounders-that is, age, sex, race/ethnicity, education, income, marital status, diabetes severity and duration, clinical CVD, and This document is copyrighted by the American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
CVD risk factors. Although adjusting for health care factors and language attenuated this relationship, its magnitude remained large. The association between immigrant status and OHA-only treatment fell short of significance; however, the observed effect sizes are potentially meaningful and achieved significance in some supplemental models, with being foreign-born people having an increased odds of OHA-only treatment. Taken together, our findings suggest that differences in pharmacological treatment of diabetes, particularly with insulin, exist along immigrant status lines. Even though the cross-sectional nature of the data constrains our ability to explore mechanisms underlying these differences, the present findings are provocative. The immigrant status differences we observed may indicate that foreign-born people receive lower intensity diabetes treatment than their U.S.-born counterparts. If so, the ramifications of these treatment differences are likely to be clinically significant, given that immigrants shoulder a considerable proportion of the diabetes burden (Oza-Frank et al., 2010; Oza-Frank & Narayan, 2010) and that lower intensity treatment could hasten the development of serious diabetes complications (Fowler, 2011) . To contextualize these findings, future studies should explore the antecedents (e.g., patient preference) and consequences (e.g., glycemic control) of immigrant status differences in diabetes treatment.
Although this study is the first to examine associations between immigrant status and differences in diabetes treatment, our findings indicate that immigrants experience these differences in a fashion analogous to racial/ethnic minority groups. To illustrate, in a sample of people with diabetes, Thackeray, Merrrill, and Neiger (2004) found that Hispanics and Asian/Pacific Islanders were less likely to take insulin and more likely to take OHAs than nonHispanic Whites. Harris, Eastman, Cowie, Flegal and Eberhardt (1999) reported similar results, finding that Mexican Americans with diabetes were more likely to be treated with OHAs than non-Hispanic Whites. Our findings are also consistent with evidence of immigrant treatment differences for other medical conditions. Prior research has found lower depression (Landa, Skritskaya, Nicasio, Humensky, & Lewis-Fernandez, 2015) and hypertension (Ursua et al., 2014) treatment rates for foreign-born groups versus U.S.-born groups. Differences in treatment adherence have also been investigated. This line of research suggests that, among immigrant groups, adherence is lower for radiotherapy (Formenti et al., 1995) , substance use treatment (Mancini, SalasWright, & Vaughn, 2015) , and tuberculosis treatment (Ailinger, Moore, Nguyen, & Lasus, 2006) but not for HIV treatment with antiretroviral medications (Vissman, Young, Wilkin, & Rhodes, 2013) or hypertension treatment (W. W. Li, Stewart, Stotts, & Froelicher, 2006) . Our findings align with the small but emerging literature on immigrant health disparities and highlight the need for future research to examine how these differences develop and the degree to which they contribute to poor health outcomes.
Several factors may explain the lower odds of insulin treatment in immigrants with diabetes that we observed. Patient-level factors often guide treatment decisions. For instance, foreign-born patients may misunderstand the importance of medication in diabetes management, leading to resistance to intensification to insulin therapy (Khunti, Davis, & Khunti, 2015) . In addition, physician-level factors, including beliefs about themselves or their patients, affect treatment decisions (Khunti et al., 2015) . For instance, physicians may believe they lack the time or skill to effectively communicate the importance of safely monitoring insulin therapy. They may also believe that foreign-born patients will demonstrate poor adherence in the event that insulin is initiated (J. B. Brown et al., 2002) . Finally, both patients and physicians are nested within broader health care systems that may directly (e.g., through lack of resources to guide appropriate care for diverse populations; J. B. Brown et al., 2002) and indirectly (e.g., through policies regarding affordable medication; K. M. Nelson, Chapko, Reiber, & Boyko, 2005) influence the capacity to give and receive equitable care. It is worth noting that patient-, physician-, and health care systemslevel factors likely exert additive and/or interactive effects on treatment decisions. Moreover, these patient-, physician-, and health care systems-level factors may be particularly decisive for foreign-born individuals living in the United States, for whom language discordance, differing cultural norms, and fluctuating social and political climates may further complicate medical decisions.
Some theoretical and clinical implications arise from our findings. Given that U.S. immigrant groups tend to cluster within racial/ethnic minority groups and that racial/ethnic minority groups experience marked health disparities (A. Nelson, 2002) , immigrant groups may be a particularly vulnerable and underserved population. Our results suggest that immigrant groups may be susceptible to diabetes treatment disparities. With respect to theory, longitudinal studies testing candidate mechanisms that contribute to potential immigrant disparities in diabetes treatment are needed-the significance of such work would be optimized by collecting data at the patient, provider, and health care system levels. Concerning clinical practice, our findings raise the possibility that integrating information about a patient's immigrant status, in addition to racial/ethnic identity, may be an important component of culturally sensitive diabetes care.
Among our study's strengths are the use of a large, nationally representative sample of U.S. adults with diabetes and data collection through interviews, physical examinations, and laboratory tests. Particularly important is that respondents who reported pastmonth medication use were asked to produce medication containers, which were verified by trained interviewers. In addition, the physical examination and laboratory components provided objective assessments of key covariates, such as BMI and HbA1c levels. Some limitations are also worth noting. First, although we adjusted our models for many potential confounders including diabetes severity and duration, we were not able to match patients on these factors that could affect the odds of receiving either treatment. Thus, we cannot completely rule out the influence of these potential confounders. Second, the cross-sectional nature of the NHANES data did not allow us to rigorously test for mediation, as we could not determine directionality between immigrant status and any candidate mediators. Third, because we selected respondents with self-reported, physician-diagnosed diabetes, it is possible that we underestimated treatment differences by immigrant status, as those who are foreign-born are more likely to have unrecognized diabetes (Barcellos, Goldman, & Smith, 2012) . Fourth, some characteristics that can make immigrant groups differentially vulnerable to health disparities were not assessed or were not assessed consistently in NHANES and could not be examined. Immigrants are an increasingly heterogeneous group (Derose et al., 2007; Hacker et al., 2011; Singh & Hiatt, 2006) varying in factors known to affect health outcomes, such as counThis document is copyrighted by the American Psychological Association or one of its allied publishers.
try of origin (Zimmerman, Kiss, & Hossain, 2011) , place of arrival (Derose et al., 2007; Zimmerman et al., 2011) , age of migration (Angel, Angel, Venegas, & Bonazzo, 2010; Colon-Lopez, Haan, Aiello, & Ghosh, 2009; Holmes, Driscoll, & Heron, 2015) , and experience with racialization and racism (Viruell-Fuentes, 2007 Viruell-Fuentes, Miranda, & Abdulrahim, 2012) . Understanding the influence of these factors is an important goal for future research and will help identify modifiable targets for interventions and policy changes designed to reduce immigrant health disparities.
In sum, the present study identified differences in pharmacological treatment of diabetes along immigrant status lines, with foreign-born individuals being about half as likely to receive insulin than their U.S.-born counterparts. This, in turn, could result in poorer glycemic control and, ultimately, an elevated incidence of serious diabetes complications among immigrants.
